BridgeBio Pharma, Inc. — Director's Dealing 2020

Oct 20, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-10-16

Reporting Person: HOMCY CHARLES J (Director, Chairman of Pharmaceuticals)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-16	Common Stock	M	10256	$17.00	Acquired	1214023	Direct
2020-10-16	Common Stock	S	10256	$41.00	Disposed	1203767	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-16	Stock Option (Right to Buy)	$17.00	M	10256	Disposed	2029-06-26	Common Stock (10256)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan that the Reporting Person adopted on December 13, 2019 and amended on August 26, 2020.

F2: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date.